“FINANCIALSAt the end of the June quarter Imugene has A$93.1...

“FINANCIALS
At the end of the June quarter Imugene has A$93.1 million in cash or equivalents (Excluding R&D tax rebate of ~$11 million expected imminently), providing a runway to support its clinical pipeline and operations into late 2025. Net cash used in operating activities for the quarter amounted to A$19 million, with direct research and development costs accounting for 57% of total costs.”

Unless the positive some might say excited words and body language coming from Professor Fong about how surprisingly good the data he is seeing is then I would wonder why with a cash runway till late 2025 anyone would be racing to a capital raise before the expected data over the next six to eight months is revealed.

I would have thought it would be difficult to even quantify how much further capital was required until the data was in and the FDA had given some indication as to what it was going to agree as being the next step.

For example if all 10 bile duct recruits have a CR the next step could be straight to a registration trial which would be an entirely different kettle of fish from a funding perspective.

My opinion only DYOR

Fact Finder